Table 5 The selected CTL epitopes of HPV L2 Protein, based on binding affinity.

From: In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine

Protein Name

Position

Epitope Sequence

No. of Alleles

Top alleles

NetMHCpan Average Rank Scores*

ProPred-I Average Scores**

Syfpeithi Average Scores**

Conservancy (= > 75%)

Allergenicity

L2

11–20 (Type 16)

KRASATQLYK

17

HLA-A03:01

HLA-B58:01

HLA-B15:01

HLA-B27:05

0.576

413.070

17.280

Type 31: 100%

Type 33: 100%

Type 35: 100%

Type 51: 100%

Type 52: 100%

Type 58: 100%

Type 56: 90%

Non-allergen

11–20 (Type 18)

KRASVTDLYK

17

HLA-A03:01

HLA-B58:01

HLA-B15:01

HLA-B27:05

0.626

415.190

17.360

Type 31: 100%

Type 33: 100%

Type 35: 100%

Type 51: 100%

Type 52: 100%

Type 58: 100%

Type 56: 90%

Non-allergen

60–71 (Type 18)

GTGSGTGGRTGY

13

HLA-A03:01

HLA-A01:01

HLA-B15:01

1.502

33.7167

11.585

Type 31: 100%

Type 33: 100%

Type 35: 100%

Type 51: 100%

Type 52: 100%

Type 58: 100%

Type 56: 90%

Non-allergen

280–291 (Type 16)

DPDFLDIVALHR

12

HLA-A01:01

HLA-A03:01

HLA-A26:01

1.198

53.281

15.375

Type 31: 100%

Type 33: 100%

Type 35: 100%

Type 51: 100%

Type 52: 100%

Type 58: 100%

Type 56: 90%

Non-allergen

293–303 (Type 16)

ALTSRRTGIRY

10

HLA-A01:01

HLA-A15:01

HLA-A26:01

0.873

42.308

14.720

Type 31: 100%

Type 33: 100%

Type 35: 100%

Type 51: 100%

Type 52: 100%

Type 58: 100%

Type 56: 90%

Non-allergen

273–284 (Type 18)

DSDFMDIIRLHR

12

HLA-A40:01

HLA-A01:01

HLA-A03:01

1.031

65.570

14.754

Type 31: 100%

Type 33: 100%

Type 35: 100%

Type 51: 100%

Type 52: 100%

Type 58: 100%

Type 56: 90%

Non-allergen

286–296 (Type 18)

ALTSRRGTVRF

10

HLA-A58:01

HLA-B27:05

HLA-B08:01

0.845

43.607

14.590

Type 31: 100%

Type 33: 100%

Type 35: 100%

Type 51: 100%

Type 52: 100%

Type 58: 100%

Type 56: 90%

Non-allergen

  1. *lower rates show better binding affinity, **Higher rates show better binding affinity.